Cognition Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
Cognition Therapeutics R&D Spending Growth & History (CGTX)
Cognition Therapeutics's r&d spending was $37.2M for fiscal 2025.
View full Cognition Therapeutics company overviewCognition Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $37.2M | −$4.5M | −10.77% |
| 2024 | 2024-12-31 | $41.7M | $4.5M | +12.04% |
| 2023 | 2023-12-31 | $37.2M | $6.9M | +22.66% |
| 2022 | 2022-12-31 | $30.3M | $11.8M | +63.28% |
| 2021 | 2021-12-31 | $18.6M | $5.7M | +44.11% |
| 2020 | 2020-12-31 | $12.9M | — | — |
Cognition Therapeutics quarterly r&d spending
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.1M | −$6.4M | −55.60% |
| Q1 2026 | 2026-03-31 | $6.1M | −$4.7M | −43.26% |
| Q4 2025 | 2025-12-31 | $11.1M | $3.0M | +36.71% |
| Q3 2025 | 2025-09-30 | $3.8M | −$7.6M | −66.88% |
| Q2 2025 | 2025-06-30 | $11.5M | −$96,000 | −0.83% |
| Q1 2025 | 2025-03-31 | $10.8M | $233,000 | +2.21% |
| Q4 2024 | 2024-12-31 | $8.2M | −$3.4M | −29.71% |
| Q3 2024 | 2024-09-30 | $11.4M | −$277,000 | −2.37% |
| Q2 2024 | 2024-06-30 | $11.6M | $3.1M | +36.25% |
| Q1 2024 | 2024-03-31 | $10.6M | $5.1M | +94.35% |
| Q4 2023 | 2023-12-31 | $11.6M | $5.2M | +80.12% |
| Q3 2023 | 2023-09-30 | $11.7M | $3.4M | +41.13% |
| Q2 2023 | 2023-06-30 | $8.5M | −$601,000 | −6.61% |
| Q1 2023 | 2023-03-31 | $5.4M | −$1.1M | −16.69% |
| Q4 2022 | 2022-12-31 | $6.4M | $867,000 | +15.56% |
| Q3 2022 | 2022-09-30 | $8.3M | $4.6M | +124.98% |
| Q2 2022 | 2022-06-30 | $9.1M | $4.2M | +85.90% |
| Q1 2022 | 2022-03-31 | $6.5M | $2.1M | +47.13% |
| Q4 2021 | 2021-12-31 | $5.6M | — | — |
| Q3 2021 | 2021-09-30 | $3.7M | $276,000 | +8.12% |
| Q2 2021 | 2021-06-30 | $4.9M | — | — |
| Q1 2021 | 2021-03-31 | $4.4M | — | — |
| Q3 2020 | 2020-09-30 | $3.4M | — | — |
Cognition Therapeutics r&d spending trends
Over the last five fiscal years, Cognition Therapeutics's r&d spending increased from $12.9M to $37.2M, a change of $24.3M. The latest reported quarter, Q2 2026, shows $5.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cognition Therapeutics source filings ↗